Amylyx Pharmaceuticals, Inc. - Common Stock — 현금 흐름 (NASDAQ:AMLX)

Financials

영업활동으로 인한 현금 -179.87 M11.92 M-167.65 M-123.34 M -120.4 M 투자 활동으로 인한 현금 -238.99 M92.05 M75.65 M14.04 M 93.96 M 재무활동으로 인한 현금 431.79 M3.54 M348 K257.03 M 194.58 M 잉여 현금 흐름 -179.87 M11.92 M-167.65 M-123.48 M -120.53 M

Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024.

AMLX

Financials

Amylyx Pharmaceuticals, Inc. - Common Stock

뉴스

H.C. Wainwright, Amylyx 목표 주가 34달러로 상향 조정

H.C. Wainwright raises Amylyx stock price target to $34 on trial confidence

애밀릭스 파마슈티컬, TD 코웬 컨퍼런스 발표: Avexitide 전략 및 전망

에이미릭스, 실적 호조에도 임상 불확실성에 3% 이상 하락

Amylyx shares fall over 3% on trial uncertainty despite earnings beat

Stifel initiates Amylyx stock with buy rating on drug potential

에일리믹스, 아베엑시티드 임상 마무리 단계 앞두고 실적 발표 예정

Amylyx set to report earnings as avexitide trial nears finish

에이미릭스 목표 주가, H.C. 웨인라이트, 28달러로 상향

Amylyx stock price target raised to $28 from $20 at H.C. Wainwright

Amylyx Pharmaceuticals: Back From The Dead (NASDAQ:AMLX)

Amylyx, 52주 신고가 경신: 주당 16.96달러